Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-06-03
2008-06-03
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S234200, C514S235500, C514S252020, C514S252110, C514S252140, C514S255050, C544S060000, C544S238000, C544S295000, C544S357000, C544S405000
Reexamination Certificate
active
07381719
ABSTRACT:
A compound of the formula (I) wherein the variables X1to X10, R1to R7including R3′, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed
REFERENCES:
patent: 4191771 (1980-03-01), Zimmerman
patent: 4891379 (1990-01-01), Zimmerman et al.
patent: 6140352 (2000-10-01), Crowell et al.
patent: 6436959 (2002-08-01), Carson et al.
patent: 0921120 (1999-09-01), None
patent: 1 072 592 (2001-01-01), None
patent: 0827746 (2002-04-01), None
patent: WO 97/10825 (1997-03-01), None
patent: WO 99/67204 (1999-12-01), None
patent: WO 00/40560 (2000-07-01), None
patent: WO 02/06276 (2002-01-01), None
patent: WO 02/38544 (2002-05-01), None
patent: WO 02/078693 (2002-10-01), None
Wentland, et al., “8-Carboxamidocyclazocine Analogues: Redefining the Structure-Activity Relationships of 2,6-Methano-3-Benzazocines,”Bioorganic&Medicinal Chemistry Letters, vol. 11, pp. 623-626 (2001).
Wentland, et al., “3-Carboxamido Analogues of Morphine and Naltrexone: Synthesis and Opioid Receptor Binding Properties,”Bioorganic&Medicinal Chemistry Letters, vol. 11, pp. 1717-1721 (2001).
Blanco-Pillado Maria-Jesus
De La Torre Marta Garcia
Diaz Buezo Nuria
Holloway William Glen
Matt James Edward
Demeter John C.
Eli Lilly and Company
Ginah Francis O.
Murray Jeffrey H
Wilson James O.
LandOfFree
Diaryl ethers as opioid receptor antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diaryl ethers as opioid receptor antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diaryl ethers as opioid receptor antagonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2814828